Background and objectives A long-term high-fat diet (HFD) exerts lipotoxic effects on multiple organs, particularly the liver, leading to metabolic diseases. This study aimed to delineate the dynamic ...

Researchers at the University of Barcelona found that combining pemafibrate and telmisartan significantly reduces liver fat ...

The liver is one of the most important regulators of systemic energy metabolism, including the coordinated uptake, storage and release of lipids. Lipid metabolism in the liver ranges from uptake of ...

A new study suggests a combination of cardiovascular drugs, pemafibrate and telmisartan, may reverse fatty liver disease by ...

In combination, two commonly used heart drugs reverse fat accumulation in the liver, a study in animals has shown.

The live zonal heterogeneity and potential correlations between metabolite composition and gene expression profiles in an MASLD mouse model, and the role of GPR35 in influencing liver zonation are ...

Your liver is one of the most vital organs in your body. It filters toxins, processes nutrients, produces bile, and supports ...

Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one-third of the adult population. This disorder is characterized by the ...

Discover a study comparing tirzepatide, semaglutide, and liraglutide in MASLD, revealing significant reductions in liver ...

Discover how chromium, a trace nutrient found in whole grains, seafood, and brewer’s yeast, might subtly shape metabolism and ...

Two drugs already approved for cardiovascular conditions – pemafibrate and telmisartan – could be used in combination to help ...